Rationale for considering GLP1 as monotherapy includes its beneficial effect on weight reduction, the simplicity of treatment schedule, and targeting the pathophysiology of youth-onset type 2 diabetes. This evidence concerns the gene GCG and type 2 diabetes mellitus.